Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The JAK2-Selective Inhibitor NS-018 Preferentially Suppresses CFU-GM Colony Formation By Bone-Marrow Cells From High-Risk Myelodysplastic Syndrome Patients

Ayumi Kodama, Haruna Naito, PhD, Yohei Nakaya, Ayako Tamura, Yoshiaki Chinen, MD, Tomohiko Taki, MD, PhD, Junya Kuroda, MD, PhD, Masafumi Taniwaki, MD, PhD

Blood (2013) 122 (21): 1286.

https://doi.org/10.1182/blood.V122.21.1286.1286

Published: 2013

Journal Articles

NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count

Yohei Nakaya, Kotaro Shide, MD, PhD, Haruna Naito, PhD, Tomoko Niwa, PhD, Tatsuya Horio, Jun Miyake, PhD, Kazuya Shimoda, MD, PhD

Blood (2013) 122 (21): 3847.

https://doi.org/10.1182/blood.V122.21.3847.3847

Published: 2013

Journal Articles

Dual Inhibition of the STAT3 and Src Pathways by NS-018, a JAK2 and Src-Family Kinase Inhibitor, Reduces Myeloma Cell Proliferation and Adhesion and Suppresses Osteoclast Formation

Kazuya Kuramoto, PhD, Ayumi Kodama, Junko Homan, Yohei Nakaya, Toshio Kitamura, MD, PhD, Haruna Naito, PhD

Blood (2011) 118 (21): 2900.

https://doi.org/10.1182/blood.V118.21.2900.2900

Published: 2011

Journal Articles

NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

Kotaro Shide, Yohei Nakaya, Takuro Kameda, Haruko Shimoda, Tomonori Hidaka, Yoko Kubuki, Keiko Katayose, Takuya Matsunaga, Junko Homan, Takashi Kotera, Hiroshi Shibayama, Haruna Naito, Kazuya Shimoda

Blood (2010) 116 (21): 4106.

https://doi.org/10.1182/blood.V116.21.4106.4106

Published: 2010

Journal Articles

Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018

Yohei Nakaya, Haruna Naito, Junko Homan, Seishi Sugahara, Tatsuya Horio, Tomoko Niwa, Kotaro Shide, Kazuya Shimoda

Blood (2010) 116 (21): 4107.

https://doi.org/10.1182/blood.V116.21.4107.4107

Published: 2010

Journal Articles

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Shinya Kimura, Haruna Naito, Hidekazu Segawa, Junya Kuroda, Takeshi Yuasa, Kiyoshi Sato, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Kimio Nasu, Tetsuo Asaki, Tomoko Niwa, Kazuko Hirabayashi, Taira Maekawa

Blood (2005) 106 (12): 3948–3954.

https://doi.org/10.1182/blood-2005-06-2209

Published: 2005

Journal Articles

Simultaneous Targeting of Lyn and Bcr-Abl Kinases by NS-187 Cures Mice Bearing Imatinib-Resistant Leukemic Cells.

Haruna Naito, PhD, Shinya Kimura, MD, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Sachie Kimura, Shinsaku Ito, Eishi Ashihara, MD, Taira Maekawa, MD, Kazuko Hirabayashi, PhD

Blood (2005) 106 (11): 1518.

https://doi.org/10.1182/blood.V106.11.1518.1518

Published: 2005

Journal Articles

A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.

Shinya Kimura, MD, Haruna Naito, PhD, Asumi Yokota, Yuri Kamitsuji, Eri Kawata, Eishi Ashihara, MD, Yohei Nakaya, Haruna Naruoka, Tatsushi Wakayama, Tetsuo Asaki, Tomoko Niwa, PhD, Kazuko Hirabayashi, PhD, Taira Maekawa, MD

Blood (2005) 106 (11): 1522.

https://doi.org/10.1182/blood.V106.11.1522.1522

Published: 2005

NARROW

The JAK2-Selective Inhibitor NS-018 Preferentially Suppresses CFU-GM Colony Formation By Bone-Marrow Cells From High-Risk Myelodysplastic Syndrome Patients

NS-018, a Selective JAK2V617F Inhibitor, Improves JAK2V617F-Induced Murine Myelofibrosis Without Decreasing The Erythrocyte Or Platelet Count

Dual Inhibition of the STAT3 and Src Pathways by NS-018, a JAK2 and Src-Family Kinase Inhibitor, Reduces Myeloma Cell Proliferation and Adhesion and Suppresses Osteoclast Formation

NS-018, a Potent Novel JAK2 Inhibitor, Effectively Treats Murine MPN Induced by the Janus Kinase 2 (JAK2) V617F Mutant

Preferential Inhibition of An Activated Form of Janus Kinase 2 (JAK2) by a Novel JAK2 Inhibitor, NS-018

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Simultaneous Targeting of Lyn and Bcr-Abl Kinases by NS-187 Cures Mice Bearing Imatinib-Resistant Leukemic Cells.

A Dual Bcr-Abl/Lyn Tyrosine Kinase Inhibitor, NS-187, Is a Novel Agent for Imatinib-Resistant Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only